Expanding Molecular Testing Leads to Personalized Care in GI CancerMarch 29th 2021
A key advance in treating patients with gastrointestinal cancer is molecular profiling of the tumor that results in specific targets being identified. The standard of care for GI cancer has consisted of surgery, radiotherapy, and chemotherapy, but these standards have had limited efficacy and considerable toxicity that impact patients’ quality of life.
Orca-T Reduces GVHD, Mortalities in Hematologic MalignanciesMarch 28th 2021
Data presented during the 2021 Transplantation and Cellular Therapy Meetings showed that treatment with Orca-T achieved a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, and a lack of treatment-related mortalities while demonstrating scalability potential.
Regorafenib/Nivolumab Proof of Concept Suggested in Third-Line, Refractory HCCMarch 28th 2021
Half of all patients with hepatocellular carcinoma treated with the combination of regorafenib and nivolumab following progression on 2 lines of chemotherapy achieved disease control, according to initial results from a phase 2 proof-of-concept trial.
Machines and Patient Power Move Biomarker Discoveries ForwardMarch 27th 2021
The biggest unanswered question in biomarker development for cancer is how to determine which patients will respond to targeted therapy or immunotherapy. Investigators around the world are trying to answer this through clinical trials and data mining, in addition to finding new tools to add to the mix.
Sintilimab With SBRT Leads to 100% Disease Control in Oligometastatic HCCMarch 25th 2021
In a single-arm study, 100% of patients treated with sintilimab plus stereotactic body radiotherapy who had oligometastases of hepatocellular carcinoma achieved disease control and were alive and progression free at 6 months.
Next-Generation Sequencing Informs Genetic Testing in Breast CancerMarch 24th 2021
As the understanding of genetic risk factors in breast cancer continues to grow, professional organizations have sought to provide specific recommendations for genetic testing that would prevent overtesting yet still diagnose as many mutations as possible in patients.
Sotorasib Impresses in Patients With KRAS G12C–Mutant NSCLCMarch 18th 2021
Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer who progressed after standard treatment, according to results from the phase 2 portion of the CodeBreaK 100 trial .